VK-2019 is an orally available small molecule that binds Epstein-Barr nuclear antigen 1 (EBNA-1) and inhibits its DNA binding activity. It is being studied in nasopharyngeal carcinoma, an EBV-associated malignancy.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
Epstein-Barr nuclear antigen 1 (EBNA-1)
Mechanism
Inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.